Evaluation of the HBV liver reservoir with fine needle aspirates

Article Gastroenterology & Hepatology

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure

Lena Allweiss et al.

Summary: A major goal of hepatitis B virus (HBV) treatments is to reduce or inactivate intrahepatic viral covalently closed circular DNA (cccDNA). There are different methods for cccDNA quantification, such as Southern blot (SB) and quantitative PCR (qPCR). This study compared various protocols for cccDNA isolation and qPCR quantification in liver tissues and cell cultures, aiming to develop evidence-based guidance for best practices.

GUT (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis

Ang Cui et al.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+T cells

Shirin Nkongolo et al.

Summary: This study identifies a distinct population of liver-resident CD8+ T cells in patients with chronic hepatitis B (CHB), which are highly activated and play a role in CHB pathogenesis by causing nonspecific killing of hepatocytes through Fas ligand-mediated mechanism.

JOURNAL OF CLINICAL INVESTIGATION (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity

Aleksei Suslov et al.

Summary: HBeAg seroconversion in chronic hepatitis B is associated with a significant decrease in serum HBV DNA levels and reduction of cccDNA content. Transition to HBeAg-negative chronic infection is characterized by strong inhibition of cccDNA transcriptional activity and reduced replication efficiency downstream of pgRNA in some patients.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections

Maria Guadalupe Martinez et al.

Summary: Current antiviral therapies for chronic hepatitis B can improve patients' quality of life but do not cure infected hepatocytes. Complete HBV cure requires therapies targeting the cccDNA pool directly. New technologies aim to achieve non-cytolytic direct cccDNA targeting for cure.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

HBV 2021: New therapeutic strategies against an old foe

Armando Andres Roca Suarez et al.

Summary: Hepatitis B virus affects over 250 million people worldwide and is a major cause of cirrhosis and liver cancer. Despite vaccination programs, HBV infection remains a public health concern with limited treatment options. Ongoing efforts are needed to develop new therapeutic strategies to eliminate HBV, with a focus on scientific rationale and recent drug discovery advancements.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Medicine, Research & Experimental